ClinicalTrials.gg
Not yet recruitingNCT05824806Updated May 31, 2024

Knee Osteoarthritis Treatment With Platelet-rich Plasma

A Phase 3 interventional study of PRP Protocol A and PRP Protocol B in Osteoarthritis, Knee, sponsored by Instituto Nacional de Traumatologia e Ortopedia. Not yet recruiting at 1 site in Brazil. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by Instituto Nacional de Traumatologia e Ortopedia · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Osteoarthritis, Knee with a site in Brazil — 12 open to participants now, 12 under way, 2 of them phase 3. Osteoarthritis, Knee · Brazil.

Planned enrollment
29th of 77
90 · median 66
Started
2024
with 6 others
Phase 3
8 of 79
2 open now
Primary completion
2025-08
later than 2 of 11 live
Registered
64th of 79
by date
Lead sponsor
2 of 79
Instituto Nacional de Traumatologia e Ortopedia

Among the 79 studies in Osteoarthritis, Knee with a site in Brazil, this one is the 29th largest by planned enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2024, is one of 8 in phase 3, reaches primary completion later than 2 of the 11 other live ones, and was the 64th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 79 studies in Osteoarthritis, Knee with a site in Brazil are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Osteoarthritis, Knee with a site in Brazil, or all of them as a file.
02

Study summary

Knee osteoarthritis (KOA) is a disease characterized by cartilage degeneration, synovium inflammation, bone remodeling, osteophyte formation, inflammations and loss of articular function. Interest on biological therapies has increased due to the recent update on KOA and its natural history. Viscosupplementation with hyaluronic acid aims to restore rheological properties of synovial fluid. Platelet rich plasma (PRP) is an autologous blood product which contains an elevated platelet concentration above the one found in blood. The goal of this study is to compare the clinical results of intra articular infiltration of hyaluronic and platelet rich plasma in the treatment of KOA, and to establish a protocol for PRP obtaining and prepare. Patients form the OA treating program will be selected and randomized into three groups (treatment with hyaluronic acid or onte of the two PRP protocols, PRP A and PRP B). Evaluation will include: subjective functional evaluation, clinical evaluation, radiological evaluation and radiological evaluation, which will be performed before treatment and 3 weeks, 3 months, 6 months and 1 year after treatment. Evaluation of PRP composition will be performed using ELISA/LUMINEX.

Key words: Knee, osteoarthritis, platelet rich plasma, viscosupplementation.

Read the detailed description
  • The goal of the study is to compare the clinical results of infiltration with hyaluronic acid and platelet-rich plasma (PRP) in the conservative treatment of mild to moderate osteoarthritis of the knee. Besides, we want to standardize two protocols for obtaining and preparing PRP for use in the treatment of mild to moderate OA of the knee.
  • The sample will consist of 90 patients with osteoarthritis of the knee being treated at the outpatient clinic of the Osteoarthritis Monitoring and Treatment Program.
  • Patients will be randomized in blocks by simple drawing of opaque envelopes before application, in 3 experimental groups, and identified as described below:

GROUP PRP Protocol A: Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP A), once a week, for three consecutive weeks; GROUP PRP Protocol B: Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP B), once a week, for three consecutive weeks; GROUP Hyaluronic acid: Composed of 30 patients who will receive an intra-articular injection of 2 mL of intra-articular hyaluronic acid (AHI), once a week, for three consecutive weeks.

  • PRP A will be prepared according to the following technique published previously elsewhere:

    1. Collection of 50 mL of peripheral blood from the antecubital vein, in sterile vacuum collection tubes of 5 mL with 10% sodium citrate; An aliquot of collected whole blood will be used to evaluate microbiological contamination;
    2. Centrifuge the whole blood for 10 minutes at 1200 rpm, at room temperature, separating the material into two different layers (erythrocytes, in the lower layer, and plasma, in the upper layer), in a 6.5 cm radius centrifuge;
    3. Separate and centrifuge the plasma for 5 minutes at 1200 rpm, creating two new layers (upper, which will be removed, lower, containing the platelets); Care must be taken to carefully aspirate the plasma from the closed tube using a syringe and needle and transfer it to a new collection tube, carefully injecting it through the cap;
    4. Prepare the material for infiltration in the knee; after preparation, it is estimated that 5 mL of PRP will be obtained, with half of the volume used for injection and the other half for composition analysis and microbiological analysis.
  • he preparation of PRP B will be carried out according to the following technique published previously elsewhere::

    a) Collection of 50 mL of peripheral blood from the antecubital vein, in sterile vacuum collection tubes of 5 mL with 10% sodium citrate; b) Centrifuge the whole blood for 15 minutes at 1500 rpm, at room temperature, separating the material into two different layers (red blood cells, in the lower layer, and plasma, in the upper layer), in a 6.5 cm radius centrifuge; e) Separate and centrifuge the plasma for 7 minutes at 3500 rpm, creating two new layers (upper, which will be removed, lower, containing the platelets); Care must be taken to carefully aspirate the plasma from the closed tube using a syringe and needle and transfer it to a new collection tube, carefully injecting it through the cap; f) Prepare the material for infiltration in the knee; after preparation, it is estimated that 5 mL of PRP will be obtained, with half of the volume used for injection and the other half for analysis of the composition.

  • All infiltrations will be performed in the outpatient procedure room using aseptic technique. The technique for application will follow the steps below:

    1. Patient sitting on the stretcher in a comfortable position, with knees flexed and blindfolded (blinding as to the treatment performed);
    2. Clean the area where the application will be performed with gauze moistened with degerming Clorhexidine;
    3. Let the chlorhexidine act for one minute and then remove it with gauze moistened with 70% alcohol;
    4. Palpation of the knee for unguided infiltration through the anterolateral approach to the knee;
    5. Perform anesthetic button on the skin and subcutaneous tissue at the infiltration site with 1 mL of 2% lidocaine without vasoconstrictor;
    6. Insert the needle attached to the syringe of the product used through the chosen path;
    7. Inject the treatment according to randomization (AHI/PRP A/PRP B);
    8. Remove the needle and empty syringe from the joint;
    9. Perform 30 knee flexion-extension cycles to distribute the product over the joint;
    10. Finalize the procedure with a simple dressing.

      • The patient should not consume fatty foods or alcoholic beverages 48 hours before the procedure;
      • If joint effusion is present, it must be aspirated before infiltration;
      • The patient should be advised to return to the hospital in case of exacerbated pain, swelling or redness in the knee;
      • NSAIDs should not be used in the week following application.
  • The clinical evaluation will consist of the following steps:

    1. Subjective functional assessment, based on WOMAC questionnaires, Knee Society Score (KSS) and visual analogue scale for pain, function and satisfaction analysis (before infiltration, on the day of the third infiltration, three months, six months and one year after infiltration; according to knee center follow-up protocol);
    2. Clinical assessment, consisting of (1) registration of demographic data (age, gender, weight, height, severity of osteoarthritis), (2) range of motion measurement, (3) assessment of the axis of the lower limbs (before infiltration , on the day of the third infiltration, three months, six months and one year after the infiltration; according to the knee cernter follow-up protocol); Radiographic evaluation with panoramic, anteroposterior and profile radiographs of the knees with load, aiming to detect alterations in the axis and joint space (before infiltration, 6 months and 1 year after infiltration, according to the knee center follow-up protocol).

      Patients will be evaluated by an observer independent of the one who applied the selected treatment.

  • The study of PRP composition will be carried out at the Cellular Technology Center following technique published previously elsewhere:

Peripheral blood samples from groups A and B will be processed to obtain PRP, with part of this product used in the application and part used to analyze the composition of the generated product.

Soon after preparation, a part of the product will be evaluated for hematological composition: total cell count, leukocytes and platelets, and mean platelet volume. The rest of the PRP will be stored, in aliquots of about 200ul, at the Cellular Technology Center, where it will remain frozen in a freezer at -80°C until the proteomic analysis (specified below) and the quantification of the factors and cytokines, through enzime linked immunoabsorbant assay and Luminex Kits: interleukin-1β, interleukin-6, interleukin-8, tumor necrosis factor-α, interferon-γ, interleukin-2, interleukin-2R, interleukin-7, interleukin-15, interleukin-17, interleukin-12p40 (pro-inflammatory cytokines); interleukin-1RA, interleukin-4, interleukin-5, interleukin-10, interleukin-13, interferon-α (anti-inflammatory cytokines); eotaxin, Interferon-gamma inducible Protein 10kDa, Membrane cofactor protein-1, interferon-γ-induced monokine, Macrophage inflammatory protein-1α, Macrophage inflammatory protein-1β (chemokines); endothelium growth factor, b-fibroblast growth factor, G-colony stimulating factor, vascular endotelium growth factor, transforming growth factor-β1, transforming growth factor-β2, transforming growth factor-β3, platelet derived growth factor-AB, platelet derived growth factor-BB, insulin growth factor-1 (growth factors).

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • osteoarthritis
  • platelet rich plasma
  • hyaluronic acid
  • knee
04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Will be included in the study:

  • Patients aged between 40 and 60 years
  • Patients with bilateral osteoarthritis of the knee according to the criteria of the American College of Rheumatology
  • Patients classified by radiographs using the Kellgren-Lawrence classification ≤ III in both knees
  • Patients showing complete knee range of motion (0 to 120°).

Exclusion criteria

Exclusion Criteria:

Will be excluded from the study:

  • Patients with a history of trauma, infection or previous surgery in the joint involved
  • Patients with axial deviation of the lower limbs (varus greater than 10° or valgus greater than 15°)
  • Patients with previous infiltration of the knee with in the last six months
  • Patients with previous infiltration of the knee with hyaluronic acid in the last year
  • Patients with inflammatory, or rheumatic diseases
  • Patients who used non sterois anti inflammatory drugs in the previous two weeks
  • Patients with >35 kg/m2
  • Patients using or anticoagulants
  • Patients with active neoplasia
  • Patients with hematologic disorders
  • Patients with secondary osteoarthritis
  • Patients with hip osteoarthritis
  • Patients with history of acute or chronic transmissible diseases
  • Patients residing outside the metropolitan region of Rio de Janeiro.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    PRP protocol A

    Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP A), once a week, for three consecutive weeks

    Biological: PRP Protocol A

  • Active comparator
    PRP protocol B

    Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP B), once a week, for three consecutive weeks

    Biological: PRP Protocol B

  • Placebo comparator
    Hyaluronic acid

    Composed of 30 patients who will receive an intra-articular injection of 2 mL of intra-articular hyaluronic acid (AHI), once a week, for three consecutive weeks.

    Device: Hyaluronic acid

Interventions

  • BiologicalPRP Protocol A

    Platelet rich plasma protocol A

  • BiologicalPRP Protocol B

    Platelet rich plasma protocol B

  • DeviceHyaluronic acid

    Hyaluronic acid

06

What researchers measure

Primary outcomes

  1. Evolution of Western Ontario and McMaster Universities Arthritis Index over time

    Subjective pain and function score changes

    Time frame: before infiltration, two weeks after first infiltration, three months, six months and one year after last infiltration

  2. Evolution of Knee society score over time

    Subjective function score changes

    Time frame: before infiltration, two weeks after first infiltration, three months, six months and one year after last infiltration

  3. Evolution of Visual analog pain scale over time

    Subjective pain scale changes

    Time frame: before infiltration, two weeks after first infiltration, three months, six months and one year after last infiltration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Aug 2025, 12 months later.

Of 36 non-industry phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2023
First posted
Apr 24, 2023
StartEst.
Aug 2024
Primary completionEst.
Aug 2025
CompletionEst.
Jul 2026
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05824806
Lead sponsor
Instituto Nacional de Traumatologia e Ortopedia
Collaborators
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Responsible party
Eduardo Branco de Sousa (Principal investigator, Instituto Nacional de Traumatologia e Ortopedia) — Principal investigator
First posted
Apr 24, 2023
Start date
Aug 2024 (estimated)
Primary completion
Aug 2025 (estimated)
Completion
Jul 2026 (estimated)
Last update
May 31, 2024

Study contacts

Eduardo B Sousa, MD, PhD
Contact
esousa@into.saude.gov.br
+55212134-5609
Marcelo Mandarino, MD, MSc
Contact
+552121345000
Eduardo B Sousa, MD, PhD
principal investigator · INTO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion